BD invests USD110M to boost US syringe production for biologics

USA—Becton, Dickinson and Company (BD) has committed USD110 million to expand its prefillable syringe manufacturing capacity in the United States.

The investment represents a strategic move to reinforce the nation’s pharmaceutical supply chain while meeting the surging demand for biologic medications and glucagon-like peptide-1 (GLP-1) therapies.

The company plans to bring Neopak Glass Prefillable Syringe production to its long-established facility in Columbus, Nebraska.

This manufacturing platform will offer two size options: 1ml and 2.25ml formats.

BD designed these syringes to accommodate diverse pharmaceutical formulation requirements, including medications with high viscosity that require specialized handling and delivery mechanisms.

The Neopak system integrates seamlessly with autoinjector devices, enabling patients to administer medications more easily in both clinical settings and at home.

This patient-centric approach aligns with the growing trend toward self-administered therapies for chronic conditions.

BD has earmarked USD100 million specifically for establishing the Neopak Glass Prefillable Syringe production line at the Columbus facility.

The company expects to begin supplying these products by mid-2026, marking a significant milestone in domestic pharmaceutical manufacturing capacity.

Beyond the primary production line, the funding will support comprehensive upgrades and capacity enhancements throughout the site.

An additional USD10 million will go toward improving cannula manufacturing capabilities at the same location.

Cannulas are the thin tubes that facilitate precise drug delivery in various medical applications.

These combined investments will create approximately 120 new positions at the Columbus facility, providing substantial economic benefits to the local community.

The Columbus site has served as an integral component of BD’s global manufacturing network for more than 75 years.

The facility already operates vertically integrated cannula design and production operations, which means it handles multiple stages of the manufacturing process under one roof.

This integration enhances quality control and operational efficiency.

BD previously announced that it would invest more than USD35 million to expand prefilled flush syringe production at the Columbus location.

That earlier commitment brought 50 additional jobs to the area.

The company’s latest announcements form part of a broader strategy to invest over USD2.5 billion in United States manufacturing operations over a five-year period.

The domestic production of Neopak Glass Prefillable Syringes addresses a critical need as pharmaceutical companies race to meet escalating demand for biologics and combination products designed to treat chronic diseases.

Patrick Jeukenne, worldwide president of BD Pharmaceutical Systems, emphasized the company’s commitment to supporting American drug delivery innovation.

He noted that the investment advances BD’s long-term growth objectives while demonstrating the company’s dedication to collaborating with biopharmaceutical innovators developing advanced therapies that require sophisticated drug-delivery solutions for patients.